Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
The adipocyte enhancer binding protein 1 is a transcriptional repressor with carboxypeptidase (CP) activity. De plus, nous expédions AEBP1 Anticorps (46) et AEBP1 Protéines (4) et beaucoup plus de produits pour cette protéine.
Showing 3 out of 15 products:
AEBP1 protein is expressed in the pyramidal neurons of human central nervous system and increased in neurons and glial cells of hippocampi and parahippocampal cortices, correlating with the progression of Alzheimer's disease.
ACLP stimulates the fibroblast-to-myofibroblast transition by promoting SMA (Montrer SMN1 Kits ELISA) expression via TGFbeta (Montrer TGFB1 Kits ELISA) signaling and promoting collagen expression through a TGFbeta (Montrer TGFB1 Kits ELISA) receptor-independent pathway.
There is no statistically significant differences in the frequency of variants in AEBP1 among the gastroschisis case group compared to a Caucasian control group.
Most ACLP knockout mice die perinatally due to abdominal issues.
Both cellular proliferation and survival were affected in AEBP1-silenced U87MG and U138MG cell lines and a significant percentage of these cells were directed towards apoptosis.
This review focuses on the recently reported regulatory functions that adipocyte enhancer-binding protein 1 (AEBP1) exerts on PPARgamma1 and LXRalpha (Montrer NR1H3 Kits ELISA) transcriptional activity in the context of macrophage cholesterol homeostasis and inflammation.
Transgenic overexpression of AEBP1 during adipogenesis coupled with a high-fat diet results in massive obesity in female transgenic mice via adipocyte hyperplasia.
ACLP and its discoidin-like domain may be novel targets for anti-myofibroblast-based therapies for the treatment of pulmonary fibrosis.
Stromal adipocyte enhancer-binding protein (AEBP1) promotes mammary epithelial cell hyperplasia via proinflammatory and hedgehog (Montrer SHH Kits ELISA) signaling
Data suggest that macrophage AEBP1 plays critical regulatory roles in atherogenesis, and it may serve as a potential therapeutic target for the prevention or treatment of atherosclerosis.
Results describe the pathophysiological features of gastroschisis in aortic carboxypeptidase-like protein knockout mice and to characterize the neuromuscular development of the eviscerated intestine.
MAPK (Montrer MAPK1 Kits ELISA) regulates the transcriptional activity of AEBP1 by a novel dual mechanism, in which MAPK (Montrer MAPK1 Kits ELISA) interaction enhances and subsequent phosphorylation decreases the DNA-binding ability of AEBP1
AEBP1 plays critical regulatory roles in macrophage cholesterol homeostasis, foam cell formation, and proinflammation.
NF-kappaB (Montrer NFKB1 Kits ELISA) activity is modulated by means of protein-protein interaction involving AEBP1 and IkappaBalpha (Montrer NFKBIA Kits ELISA).
AEBP1 negatively regulates adipose tissue PTEN levels and has a key functional role in modulation of in vivo adiposity.
Adipocyte enhancer-binding protein 1 (AEBP1) is up-regulated during monocyte differentiation.
The adipocyte enhancer binding protein 1 is a transcriptional repressor with carboxypeptidase (CP) activity. This protein binds to a regulatory sequence, adipocyte enhancer 1 (AE-1), located in the proximal promoter region of the adipose P2 (aP2) gene, which encodes the adipocyte fatty-acid binding protein. It is characterized as a member of the regulatory B-like CP family. This protein seems to be activated by a novel mechanism, whereby the direct binding of DNA enhances its protease activity. Adipocyte-enhancer binding protein 1 may play a role in differentiated vascular smooth muscle cells.
AE binding protein 1
, adipocyte enhancer-binding protein 1
, aortic carboxypeptidase-like protein
, AE-binding protein 1